A Risk-Benefit Assessment of Anthracycline Antibiotics in Antineoplastic Therapy
- 1 December 1996
- journal article
- review article
- Published by Springer Nature in Drug Safety
- Vol. 15 (6) , 406-429
- https://doi.org/10.2165/00002018-199615060-00005
Abstract
No abstract availableKeywords
This publication has 94 references indexed in Scilit:
- Systemic Therapy of Advanced Breast CancerDrugs, 1992
- New anthracycline derivatives: What for?European Journal of Cancer and Clinical Oncology, 1991
- Chemotherapy for invasive thymoma. A 13-year experienceCancer, 1991
- Morpholinyl anthracyclines: Option for reversal of anthracycline resistanceEuropean Journal of Cancer and Clinical Oncology, 1990
- Diverse prognosis in metastatic breast cancer: Who should be offered alternative initial therapies?Breast Cancer Research and Treatment, 1989
- Protective Effect of the Bispiperazinedione ICRF-187 against Doxorubicin-Induced Cardiac Toxicity in Women with Advanced Breast CancerNew England Journal of Medicine, 1988
- Improving the Quality of Life during Chemotherapy for Advanced Breast CancerNew England Journal of Medicine, 1987
- A comparative trial of daunorubicin, cytosine arabinoside, and thioguanine, and a combination of the three agents for the treatment of acute myelocytic leukemiaMedical and Pediatric Oncology, 1979
- Chemotherapy of advanced soft-tissue sarcomas in adultsCancer Treatment Reviews, 1977
- Hydroxyldaunomycin (adriamycin) combination chemotherapy in malignant lymphomaCancer, 1976